He J - Search Results

1

Knockdown of ZBTB7A inhibits cell proliferation of breast cancer through regulating the ubiquitination of estrogen receptor alpha.

Xiao X, Shen Y, Yin L, He J, Ni X, Luo G, Chen X, Zhu W, Zhong J, Liu J, Peng X, Zu X. Xiao X, et al. Among authors: he j. Life Sci. 2019 Dec 15;239:117042. doi: 10.1016/j.lfs.2019.117042. Epub 2019 Nov 9. Life Sci. 2019. PMID: 31715186

2

Axl inhibitors as novel cancer therapeutic agents.

Shen Y, Chen X, He J, Liao D, Zu X. Shen Y, et al. Among authors: he j. Life Sci. 2018 Apr 1;198:99-111. doi: 10.1016/j.lfs.2018.02.033. Epub 2018 Feb 27. Life Sci. 2018. PMID: 29496493 Review.

3

Safety and efficacy of enhanced recovery after surgery (ERAS) programs in patients undergoing hepatectomy: A prospective randomized controlled trial.

Qi S, Chen G, Cao P, Hu J, He G, Luo J, He J, Peng X. Qi S, et al. Among authors: he g, he j. J Clin Lab Anal. 2018 Jul;32(6):e22434. doi: 10.1002/jcla.22434. Epub 2018 Mar 24. J Clin Lab Anal. 2018. PMID: 29574998 Free PMC article.

4

β-catenin regulates IRF3-mediated innate immune signalling in colorectal cancer.

Ding C, He J, Zhao J, Li J, Chen J, Liao W, Zeng Y, Zhong J, Wei C, Zhang L, Zhou M, Jia Z, Zhang Y, Li H, Zhou Y, Xiao X, Han D, Li C, Zhu Z, Xia Z, Peng J. Ding C, et al. Among authors: he j. Cell Prolif. 2018 Oct;51(5):e12464. doi: 10.1111/cpr.12464. Epub 2018 Jul 13. Cell Prolif. 2018. PMID: 30004146 Free PMC article.

5

Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.

Shen Y, Zhang W, Liu J, He J, Cao R, Chen X, Peng X, Xu H, Zhao Q, Zhong J, Ding W, Lei X, Jiang Y, Zu X. Shen Y, et al. Among authors: he j. Int J Cancer. 2019 Feb 1;144(3):651-664. doi: 10.1002/ijc.31915. Epub 2018 Nov 7. Int J Cancer. 2019. PMID: 30289981

6

Self-Renewal Signalling Pathway Inhibitors: Perspectives on Therapeutic Approaches for Cancer Stem Cells.

Zhu Q, Shen Y, Chen X, He J, Liu J, Zu X. Zhu Q, et al. Among authors: he j. Onco Targets Ther. 2020 Jan 16;13:525-540. doi: 10.2147/OTT.S224465. eCollection 2020. Onco Targets Ther. 2020. PMID: 32021295 Free PMC article. Review.

7

Identification of an AXL kinase inhibitor in triple-negative breast cancer by structure-based virtual screening and bioactivity test.

Li P, Niu Y, Li S, Zu X, Xiao M, Yin L, Feng J, He J, Shen Y. Li P, et al. Among authors: he j. Chem Biol Drug Des. 2022 Feb;99(2):222-232. doi: 10.1111/cbdd.13977. Epub 2021 Oct 29. Chem Biol Drug Des. 2022. PMID: 34679238

8

Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer.

Xiao M, He J, Yin L, Chen X, Zu X, Shen Y. Xiao M, et al. Among authors: he j. Front Immunol. 2021 Dec 17;12:799428. doi: 10.3389/fimmu.2021.799428. eCollection 2021. Front Immunol. 2021. PMID: 34992609 Free PMC article. Review.

9

Inhibitory effect of the novel tyrosine kinase inhibitor DCC-2036 on triple-negative breast cancer stem cells through AXL-KLF5 positive feedback loop.

Shen Y, Zhu Q, Xiao M, Yin L, Feng W, Feng J, He J, Li P, Chen X, Ding W, Zhong J, Zeng Z, Xie Z, Liu J, Zu X. Shen Y, et al. Among authors: he j. Cell Death Dis. 2022 Aug 30;13(8):749. doi: 10.1038/s41419-022-05185-x. Cell Death Dis. 2022. PMID: 36042208 Free PMC article.

10

Icaritin induces apoptosis of HepG2 cells via the JNK1 signaling pathway independent of the estrogen receptor.

He J, Wang Y, Duan F, Jiang H, Chen MF, Tang SY. He J, et al. Planta Med. 2010 Nov;76(16):1834-9. doi: 10.1055/s-0030-1250042. Epub 2010 Jun 17. Planta Med. 2010. PMID: 20560114

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35,026 results

Search Page

Filters